| 17.38 -0.72 (-3.98%) | 07-21 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 21.19 | 1-year : | 24.76 |
| Resists | First : | 18.14 | Second : | 21.19 |
| Pivot price | 15.92 |
|||
| Supports | First : | 15.55 | Second : | 13.94 |
| MAs | MA(5) : | 16.82 |
MA(20) : | 15.8 |
| MA(100) : | 18.57  |
MA(250) : | 17.65 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 92 |
D(3) : | 86 |
| RSI | RSI(14): 57.4 |
|||
| 52-week | High : | 29.64 | Low : | 9.97 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TNDM ] has closed below upper band by 8.9%. Bollinger Bands are 46.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 18.18 - 18.25 | 18.25 - 18.33 |
| Low: | 16.53 - 16.6 | 16.6 - 16.68 |
| Close: | 17.97 - 18.11 | 18.11 - 18.24 |
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Mon, 20 Jul 2026
Tandem Diabetes Care Inc (TNDM) Shares Surge 6.0% -- What GF Sco - GuruFocus
Sat, 18 Jul 2026
When Will Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Become Profitable? - 富途牛牛
Sat, 18 Jul 2026
Can Tandem Diabetes Care (TNDM) Turn Revenue Beats Into Durable Returns On Capital? - simplywall.st
Fri, 17 Jul 2026
Tandem Diabetes Care Inc (TNDM) Shares Surge 4.9% -- What GF Sco - GuruFocus
Fri, 17 Jul 2026
Form 4 Tandem Diabetes Care Inc For: 17 July By Investing.com - Investing.com Nigeria
Fri, 17 Jul 2026
Tandem Diabetes Care (TNDM) COO logs RSU vesting, 31,741 shares held after tax withholding - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 69 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 117.3 (%) |
| Shares Short | 12,730 (K) |
| Shares Short P.Month | 11,790 (K) |
| EPS | -1.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.92 |
| Profit Margin | -9.2 % |
| Operating Margin | -7.1 % |
| Return on Assets (ttm) | -3.7 % |
| Return on Equity (ttm) | -65.8 % |
| Qtrly Rev. Growth | 5.5 % |
| Gross Profit (p.s.) | 8.23 |
| Sales Per Share | 15.02 |
| EBITDA (p.s.) | -0.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 20 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -12.69 |
| PEG Ratio | 0 |
| Price to Book value | 9 |
| Price to Sales | 1.15 |
| Price to Cash Flow | 60.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|